KM, Meiji Initiate PIII Pediatric Trial for XBB.1.5-Adapted COVID Vaccine

KM Biologics and Meiji Seika Pharma said on December 6 that they have kicked off a domestic PIII pediatric clinical trial of the inactivated vaccine “KD-414 (XBB.1.5)” against the COVID-19 Omicron variant XBB.1.5. The trial, launched the previous day, will...read more